171 related articles for article (PubMed ID: 35940942)
1. CD33 isoforms in microglia and Alzheimer's disease: Friend and foe.
Eskandari-Sedighi G; Jung J; Macauley MS
Mol Aspects Med; 2023 Apr; 90():101111. PubMed ID: 35940942
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice.
Eskandari-Sedighi G; Crichton M; Zia S; Gomez-Cardona E; Cortez LM; Patel ZH; Takahashi-Yamashiro K; St Laurent CD; Sidhu G; Sarkar S; Aghanya V; Sim VL; Tan Q; Julien O; Plemel JR; Macauley MS
Mol Neurodegener; 2024 May; 19(1):42. PubMed ID: 38802940
[TBL] [Abstract][Full Text] [Related]
3. Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease.
Gonzalez-Gil A; Porell RN; Fernandes SM; Maenpaa E; Li TA; Li T; Wong PC; Aoki K; Tiemeyer M; Yu ZJ; Orsburn BC; Bumpus NN; Matthews RT; Schnaar RL
J Biol Chem; 2022 Jun; 298(6):101960. PubMed ID: 35452678
[TBL] [Abstract][Full Text] [Related]
4. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing.
Malik M; Simpson JF; Parikh I; Wilfred BR; Fardo DW; Nelson PT; Estus S
J Neurosci; 2013 Aug; 33(33):13320-5. PubMed ID: 23946390
[TBL] [Abstract][Full Text] [Related]
5. CD33 in Alzheimer's disease.
Jiang T; Yu JT; Hu N; Tan MS; Zhu XC; Tan L
Mol Neurobiol; 2014 Feb; 49(1):529-35. PubMed ID: 23982747
[TBL] [Abstract][Full Text] [Related]
6. The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool.
Siddiqui SS; Springer SA; Verhagen A; Sundaramurthy V; Alisson-Silva F; Jiang W; Ghosh P; Varki A
J Biol Chem; 2017 Sep; 292(37):15312-15320. PubMed ID: 28747436
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation.
Griciuc A; Federico AN; Natasan J; Forte AM; McGinty D; Nguyen H; Volak A; LeRoy S; Gandhi S; Lerner EP; Hudry E; Tanzi RE; Maguire CA
Hum Mol Genet; 2020 Oct; 29(17):2920-2935. PubMed ID: 32803224
[TBL] [Abstract][Full Text] [Related]
8. Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex.
Walker DG; Whetzel AM; Serrano G; Sue LI; Beach TG; Lue LF
Neurobiol Aging; 2015 Feb; 36(2):571-82. PubMed ID: 25448602
[TBL] [Abstract][Full Text] [Related]
9. CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review.
Zhao L
Gerontology; 2019; 65(4):323-331. PubMed ID: 30541012
[TBL] [Abstract][Full Text] [Related]
10. CD33 rs2455069 SNP: Correlation with Alzheimer's Disease and Hypothesis of Functional Role.
Tortora F; Rendina A; Angiolillo A; Di Costanzo A; Aniello F; Donizetti A; Febbraio F; Vitale E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408990
[TBL] [Abstract][Full Text] [Related]
11. Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk.
McQuade A; Blurton-Jones M
J Mol Biol; 2019 Apr; 431(9):1805-1817. PubMed ID: 30738892
[TBL] [Abstract][Full Text] [Related]
12. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.
Griciuc A; Patel S; Federico AN; Choi SH; Innes BJ; Oram MK; Cereghetti G; McGinty D; Anselmo A; Sadreyev RI; Hickman SE; El Khoury J; Colonna M; Tanzi RE
Neuron; 2019 Sep; 103(5):820-835.e7. PubMed ID: 31301936
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CD33 as a genetic risk factor for Alzheimer's disease.
Estus S; Shaw BC; Devanney N; Katsumata Y; Press EE; Fardo DW
Acta Neuropathol; 2019 Aug; 138(2):187-199. PubMed ID: 30949760
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Alzheimer's disease-associated CD33 results in an inflammatory human microglia phenotype.
Wißfeld J; Nozaki I; Mathews M; Raschka T; Ebeling C; Hornung V; Brüstle O; Neumann H
Glia; 2021 Jun; 69(6):1393-1412. PubMed ID: 33539598
[TBL] [Abstract][Full Text] [Related]
15. The CD33 short isoform is a gain-of-function variant that enhances Aβ
Bhattacherjee A; Jung J; Zia S; Ho M; Eskandari-Sedighi G; St Laurent CD; McCord KA; Bains A; Sidhu G; Sarkar S; Plemel JR; Macauley MS
Mol Neurodegener; 2021 Mar; 16(1):19. PubMed ID: 33766097
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.
Griciuc A; Serrano-Pozo A; Parrado AR; Lesinski AN; Asselin CN; Mullin K; Hooli B; Choi SH; Hyman BT; Tanzi RE
Neuron; 2013 May; 78(4):631-43. PubMed ID: 23623698
[TBL] [Abstract][Full Text] [Related]
17. The age-related microglial transformation in Alzheimer's disease pathogenesis.
Yuan C; Aierken A; Xie Z; Li N; Zhao J; Qing H
Neurobiol Aging; 2020 Aug; 92():82-91. PubMed ID: 32408056
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease.
Gao C; Shen X; Tan Y; Chen S
J Neuroinflammation; 2022 Sep; 19(1):215. PubMed ID: 36058959
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis.
Salminen A; Kaarniranta K; Kauppinen A
Neurochem Int; 2021 Nov; 150():105186. PubMed ID: 34530055
[TBL] [Abstract][Full Text] [Related]
20. CD33M inhibits microglial phagocytosis, migration and proliferation, but the Alzheimer's disease-protective variant CD33m stimulates phagocytosis and proliferation, and inhibits adhesion.
Butler CA; Thornton P; Brown GC
J Neurochem; 2021 Jul; 158(2):297-310. PubMed ID: 33720433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
